☆ 4.5 Article

Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study

ADVANCES IN THERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, Research & Experimental

Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study

Pierre-Dominique Ghislain et al.

Summary: This study evaluated the real-world use and effectiveness of apremilast in the treatment of moderate to severe psoriasis in Belgium. The results showed that apremilast had a positive impact on the disease and improved patients' quality of life.

ADVANCES IN THERAPY (2022)

添加到收藏夹

Article Dermatology

Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks

Nicoletta Bernardini et al.

Summary: Psoriasis is a common chronic inflammatory skin disease associated with arthritis and systemic symptoms. Apremilast, a novel oral agent, has been used for treating moderate-to-severe plaque psoriasis and psoriatic arthritis. However, there is a lack of real-world experience with Apremilast in cancer patients with moderate-to-severe plaque psoriasis.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Dermatology

Incorporating Patient-Reported Outcomes as a Vital Sign for Dermatologic Clinical Care and Clinical Investigations

Aaron M. Secrest et al.

Summary: Patient-reported outcomes (PROs) provide comprehensive and informative assessments of patients' experiences with skin diseases, which may not necessarily correlate with clinician assessments. PROs should serve as vital signs for skin in dermatology.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

Mark Lebwohl et al.

Summary: The UPLIFT survey found that patients with PsO and PsA experienced a high disease burden, even in those with limited skin involvement. There were differences in perceptions between patients and dermatologists, highlighting an opportunity for better alignment and management of PsO and PsA. The survey was conducted during the COVID-19 pandemic, which may have impacted assessments and in-person visits.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Article Dermatology

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO

Kristian Reich et al.

Summary: In routine clinical care in Germany, patients with moderate to severe plaque psoriasis benefited from apremilast treatment up to approximately 13 months, consistent with findings from clinical trials, with a good safety profile.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Article Dermatology

Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study

Toni Maria Klein et al.

Summary: The real-world APPRECIATE study showed significant improvements in disease severity measures and clinically meaningful treatment benefits with apremilast for patients with psoriasis. Patients who received apremilast earlier in treatment management reported greater improvements in patient-relevant treatment outcomes.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Article Dermatology

A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naive adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study

D. Ioannides et al.

Summary: This study evaluated the effectiveness and safety of apremilast in bio-naive patients with moderate psoriasis in real-world clinical settings. The results showed that apremilast is a safe and effective treatment for these patients, with improvements in quality of life.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Article Dermatology

Apremilast Survival and Reasons for Discontinuation in Psoriasis: Five-Year Experience From a Greek Tertiary Care Centre

Elena Sotiriou et al.

Summary: This study investigated the drug survival of apremilast in a cohort of psoriasis patients in a Greek hospital. The results showed that approximately half of the patients continued to use the medication after 1 year.

DERMATOLOGY PRACTICAL & CONCEPTUAL (2022)

添加到收藏夹

Article Dermatology

Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study

M. Augustin et al.

Summary: The APPRECIATE study found that treatment with apremilast significantly improved the disease condition of patients with psoriasis, with 7 out of 10 patients continuing therapy and showing notable improvement in PASI scores and DLQI scores after 6 months of treatment.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Dermatology

Joint AADeNPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Craig A. Elmets et al.

Summary: This guideline addresses important clinical questions in psoriasis management and care, providing treatment recommendations and emphasizing the role of dermatologists in monitoring and educating patients, focusing on benefits and risks.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience

Giulia Radi et al.

Summary: The study aimed to report the efficacy and safety results of apremilast in clinical practice for patients with moderate-to-severe plaque psoriasis, showing that about half of the patients achieved good efficacy after 24 and 52 weeks of treatment, and 60% of patients reached and maintained DLQI 0-1 levels from week 24 to week 52.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Dermatology

Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council

Bruce Strober et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Review Urology & Nephrology

The global epidemiology of hypertension

Katherine T. Mills et al.

NATURE REVIEWS NEPHROLOGY (2020)

添加到收藏夹

Letter Dermatology

Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period

M. Megna et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Review Dermatology

Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature

Deepak M. W. Balak et al.

DERMATOLOGY AND THERAPY (2020)

添加到收藏夹

Article Dermatology

Drug survival of apremilast in a real-world setting

Megumi Kishimoto et al.

JOURNAL OF DERMATOLOGY (2019)

添加到收藏夹

Article Dermatology

Apremilast in psoriasis - a prospective real-world study

I. Vujic et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

添加到收藏夹

Article Dermatology

Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry

Bruce Strober et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

添加到收藏夹

Article Dermatology

Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis

E. Papadavid et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

添加到收藏夹

Review Rheumatology

Epidemiology of Psoriasis and Psoriatic Arthritis in Italy-a Systematic Review

Francesca Prignano et al.

CURRENT RHEUMATOLOGY REPORTS (2018)

添加到收藏夹

Article Dermatology

Real-World Experience With Apremilast in Treating Psoriasis

Julia N. Mayba et al.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2017)

添加到收藏夹

Article Dermatology

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

K. Reich et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

添加到收藏夹

Review Dermatology

A systematic review of worldwide epidemiology of psoriasis

I. M. Michalek et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

添加到收藏夹

Article Dermatology

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul et al.

BRITISH JOURNAL OF DERMATOLOGY (2015)

添加到收藏夹

Article Dermatology

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)

添加到收藏夹

Article Dermatology

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

Mark G. Lebwohl et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)

添加到收藏夹

Article Dermatology

Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis

Julia Feuerhahn et al.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003-2011

April W. Armstrong et al.

PLOS ONE (2012)

添加到收藏夹

Article Rheumatology

Measures of Psoriatic Arthritis Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)

Philip J. Mease

ARTHRITIS CARE & RESEARCH (2011)

添加到收藏夹

Article Dermatology

The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases

Matthias Augustin et al.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2009)

添加到收藏夹

Review Dermatology

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

Alexa B. Kimball et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)

添加到收藏夹

Article Medicine, General & Internal

Psoriasis 1 - Pathogenesis and clinical features of psoriasis

Christopher E. M. Griffiths et al.

LANCET (2007)

添加到收藏夹

Article Psychiatry

Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach

Jochen Schmitt et al.

GENERAL HOSPITAL PSYCHIATRY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.